Sugi Predict

Sugi Predict / Compounds / SCHEMBL4778890

SCHEMBL4778890

SCHEMBL4778890

CC(C)(C)OC(=O)N[C@H]1CC[C@H](CO)OC1

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 2/20 0.46
▸ KDM1A O60341 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ CTSK P43235 2/20 0.43
▸ GAA P10253 2/20 0.41
▸ EPHX1 P07099 1/20 0.40
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ DRD2 P14416 2/20 0.39
▸ EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30642259 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL12528145 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL30772643 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL603316 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL19898629 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL603315 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL12527248 0.88 BTK (0.43) BTKKDM1AMAOBCTSKGAA
SCHEMBL9885693 0.88 BTK (0.43) BTKKDM1AMAOBCTSKGAA
SCHEMBL12527395 0.88 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL22623131 0.87 BTK (0.40) BTKKDM1AMAOBCTSKGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4698530-A1 NK3 MODULATORS AND USES THEREOF Kallyope, Inc. (US) 2026-02-25 — — EP disclosed
US-12281114-B2 NK3 modulators and uses thereof KALLYOPE, INC. (US) 2025-04-22 — — US disclosed
WO-2024220539-A1 NK3 MODULATORS AND USES THEREOF KALLYOPE, INC. (US) 2024-10-24 — — WO disclosed
US-12030885-B2 Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2024-07-09 — — US disclosed
US-20240124469-A1 PIM KINASE INHIBITOR HANGZHOU BIOSUN PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 — — US disclosed
US-11939320-B2 Modulators of the integrated stress pathway ABBVIE INC. (US) 2024-03-26 — — US disclosed
EP-4289847-A1 PIM KINASE INHIBITOR Hangzhou Biosun Pharmaceutical Co., Ltd. (CN) 2023-12-13 — — EP disclosed
CN-115991706-A PIM kinase inhibitors 杭州邦顺制药有限公司 2023-04-21 — — CN disclosed
CN-114409656-B PIM kinase inhibitors 杭州邦顺制药有限公司 2022-09-23 — — CN disclosed
WO-2022166860-A1 PIM KINASE INHIBITOR 杭州邦顺制药有限公司 2022-08-11 — — WO disclosed
US-20220251087-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2022-08-11 — — US disclosed
US-20220213078-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INTERNATIONAL GMBH (DE) 2022-07-07 — — US disclosed
US-20220213078-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INTERNATIONAL GMBH (DE) 2022-07-07 — — US disclosed
CN-114409656-A PIM kinase inhibitors 杭州邦顺制药有限公司 2022-04-29 — — CN disclosed
US-11020398-B2 Amino-pyrrolopyrimidinone compounds and methods of use thereof ARQULE, INC. (US) 2021-06-01 — — US disclosed
CN-112166113-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2021-01-01 — — CN disclosed
WO-2020216764-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INTERNATIONAL GMBH (DE) 2020-10-29 — — WO disclosed
US-20180055846-A1 AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF ARQULE, INC. 2018-03-01 — — US disclosed
EP-1996579-A2 ANTIBIOTIC COMPOUNDS Actelion Pharmaceuticals Ltd. (CH) 2008-12-03 — — EP disclosed
WO-2007105154-A2 ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2007-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030885-B2 Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors PIK3CG, PIK3CD, PIK3R5 BTK 50/4885KDM1A 2234/4885MAOB 3733/4885
US-12281114-B2 NK3 modulators and uses thereof TAC3, TACR3, TACR2 BTK 2037/4885KDM1A 4167/4885MAOB 2869/4885
US-20220213078-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY CRH, AVPR2, CRHR2 BTK 4064/4885KDM1A 4767/4885MAOB 634/4885
US-20240124469-A1 PIM KINASE INHIBITOR PIM1, PIM2, PIM3 BTK 97/4885KDM1A 392/4885MAOB 4514/4885
US-11020398-B2 Amino-pyrrolopyrimidinone compounds and methods of use thereof BTK, SYK, LCK BTK 1/4885KDM1A 1485/4885MAOB 1170/4885
US-11939320-B2 Modulators of the integrated stress pathway ATF4, ATF1, DDIT3 BTK 2441/4885KDM1A 4651/4885MAOB 2933/4885
US-20220251087-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD BTK 33/4885KDM1A 2054/4885MAOB 2129/4885
US-20180055846-A1 AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF BTK, SYK, LCK BTK 1/4885KDM1A 1485/4885MAOB 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.